Medigen Biotechnology Corp. (TPEX:3176)

Medigen Biotechnology Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	869.74	1,388	2,223	2,041	2,145	2,207
Short-Term Investments	1,606	1,200	2,364	3,040	800	-
Trading Asset Securities	0.56	0.59	0.49	54.23	53.6	54.2
Cash & Short-Term Investments	2,476	2,588	4,588	5,135	2,998	2,261
Cash Growth	-4.82%	-43.58%	-10.67%	71.28%	32.62%	146.78%
Accounts Receivable	333.39	286.07	328.89	398.31	800.22	151.21
Other Receivables	23.71	87.61	124.72	66.37	35.46	130.51
Receivables	357.1	373.67	453.61	464.69	835.68	281.72
Inventory	694.58	645.06	546.91	692.62	752.87	323.29
Prepaid Expenses	-	22.76	33.61	382.35	99.59	-
Other Current Assets	86.67	31.36	86.4	57.93	231.96	155.9
Total Current Assets	3,615	3,661	5,708	6,733	4,918	3,022
Property, Plant & Equipment	1,922	1,981	2,043	2,198	2,189	2,166
Long-Term Investments	565.97	640.35	292.87	307.33	363.71	156.49
Goodwill	-	76.18	76.18	76.18	76.18	76.18
Other Intangible Assets	96.98	24.18	30.36	36.9	48.08	79.34
Long-Term Deferred Tax Assets	254.99	253.21	327.5	480.94	522.18	555.68
Other Long-Term Assets	52.11	74.12	49.1	150.42	81.75	97.02
Total Assets	6,507	6,710	8,527	9,982	8,199	6,152
Accounts Payable	103.84	125.29	122.57	185.01	163.94	110
Short-Term Debt	194.6	229.8	402.6	328	300	475
Current Portion of Long-Term Debt	37.51	47.35	1,728	28.86	21.34	21.39
Current Portion of Leases	21.69	22	17.32	13.13	3.32	3.02
Current Income Taxes Payable	16.53	12.73	24.63	22.99	-	-
Current Unearned Revenue	160.28	231.23	135	130.4	244.42	113.92
Other Current Liabilities	281.63	256.82	349.37	343.94	331.89	210.47
Total Current Liabilities	816.08	925.22	2,780	1,052	1,065	933.8
Long-Term Debt	392.42	411.25	449.1	2,129	470.77	486.37
Long-Term Leases	297.32	308	267.53	275.32	196.64	195.67
Long-Term Deferred Tax Liabilities	14.07	14.08	14.15	14.24	14.35	18.15
Other Long-Term Liabilities	10.12	10.28	10.28	29.53	15.89	7.62
Total Liabilities	1,532	1,672	3,530	3,511	1,773	1,653
Common Stock	1,393	1,393	1,393	1,394	1,394	1,390
Additional Paid-In Capital	624.56	536.79	968.14	1,562	1,109	1,101
Retained Earnings	-288.23	-352.66	-747.51	-727.98	-52.82	-631.38
Comprehensive Income & Other	-38.29	4.69	-22.45	-34.12	-54.96	-44.37
Total Common Equity	1,691	1,582	1,592	2,194	2,394	1,815
Minority Interest	3,283	3,456	3,405	4,277	4,032	2,684
Shareholders' Equity	4,975	5,038	4,997	6,471	6,426	4,499
Total Liabilities & Equity	6,507	6,710	8,527	9,982	8,199	6,152
Total Debt	943.54	1,018	2,865	2,774	992.07	1,181
Net Cash (Debt)	1,533	1,570	1,723	2,361	2,006	1,079
Net Cash Growth	-4.02%	-8.86%	-27.03%	17.68%	85.87%	-
Net Cash Per Share	10.95	11.27	12.36	16.97	14.44	7.77
Filing Date Shares Outstanding	140.82	139.31	139.35	139.45	139.36	138.99
Total Common Shares Outstanding	140.82	139.31	139.35	139.45	139.36	138.99
Working Capital	2,798	2,736	2,928	5,681	3,853	2,088
Book Value Per Share	12.01	11.36	11.42	15.73	17.18	13.06
Tangible Book Value	1,594	1,482	1,485	2,081	2,270	1,660
Tangible Book Value Per Share	11.32	10.64	10.66	14.92	16.29	11.94
Land	-	330.29	330.29	354.04	354.04	354.04
Buildings	-	1,468	1,465	1,506	1,500	1,495
Machinery	-	1,233	1,266	1,240	1,178	1,002
Construction In Progress	-	2.57	21.37	14.54	4.7	17.9
Leasehold Improvements	-	9.35	3.34	3.03	2.55	1.89

Source: S&P Global Market Intelligence. Standard template. Financial Sources.